{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-134588","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.003649+00:00","generated_at":"2026-06-16T00:55:35.248186+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Soleno completes enrollment in DCCR PWS study; triggers $10M capital infusion","bullets":["Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.","Top-line data expected Q3 2023; FDA previously acknowledged data could support an NDA submission.","Completion triggers $10 million capital infusion from Nantahala, Abingworth, and Vivo per Dec 2022 SPA.","77 patients enrolled at 17 US and 5 UK sites; 93% of total 83 patients participated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-134588","json":"https://secwatch.observer/filing/0001193125-23-134588.json","markdown":"https://secwatch.observer/filing/0001193125-23-134588.md","text":"https://secwatch.observer/filing/0001193125-23-134588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523134588/0001193125-23-134588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523134588/d363623d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:55:35.248186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}